Xeris Pharmaceuticals, Inc. (XERS) Social Stream



Xeris Pharmaceuticals, Inc. (XERS): $3.18

0.10 (+3.25%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add XERS to Watchlist
Sign Up

XERIS BIOPHARMA HOLDINGS INC (XERS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering XERS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-29 4 $11 $4 $7.75 $2.93 164.51%
2021-11-11 5 $11 $4.25 $7.062 $2.93 141.02%
2021-12-14 5 $11 $4.25 $6.85 $2.93 133.79%
2021-12-31 5 $11 $5.4 $7.08 $2.93 141.64%
2022-01-10 5 $11 $5.4 $7.48 $2.93 155.29%
2022-02-01 5 $11 $6 $7.6 $2.93 159.39%
2022-03-23 4 $7 $6 $6.25 $2.93 113.31%
2022-05-12 5 $7 $6 $6.3 $2.93 115.02%
2022-10-19 4 $6.5 $6 $6.125 $2.93 109.04%
2022-10-21 5 $6.5 $4 $5.7 $2.93 94.54%
2022-11-10 5 $6.5 $4 $5.5 $2.93 87.71%
2023-03-09 5 $6 $4 $5 $2.93 70.65%
2023-08-10 4 $6 $4 $5 $2.93 70.65%
2023-11-09 5 $6 $4 $4.9 $2.93 67.24%
2023-11-13 5 $5.5 $4 $4.6 $2.93 57%

The Trend in the Analyst Price Target


Over the past 22 months, XERS's average price target has gone down $3.

XERS reports an average of 203.78% for its upside potential over the past 41 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-09 5 6 4 5.0 1.25 300%
2023-03-09 4 6 4 5.0 1.25 300%
2023-05-10 4 6 4 5.0 2.93 70.65%
2023-07-25 4 6 4 5.0 2.41 107.47%
2023-08-28 5 6 4 4.9 2.27 115.86%

XERS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 5 0 0 0 0 5

The Trend in the Broker Recommendations


XERS's average broker recommendation rating improved by 0.75 over the prior 29 months.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • To contextualize these metrics, consider that out of all US stocks, XERIS BIOPHARMA HOLDINGS INC's average analyst price target is higher than 122.06% of them.
  • To contextualize these metrics, consider that out of all US stocks, XERIS BIOPHARMA HOLDINGS INC's number of analysts covering the stock is higher than 383.88% of them.
  • XERIS BIOPHARMA HOLDINGS INC's variance in analysts' estimates is lower than -801.88% of Healthcare stocks.
  • XERS has a higher upside potential (average analyst target price relative to current price) than 1201.03% of stocks in the small market cap category.

Stocks similar to XERIS BIOPHARMA HOLDINGS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are VRCA, ITRM, and KNSA.

Make investment decisions regarding XERS using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!